Navigation Links
Boston Scientific Announces Results for Fourth Quarter and Full Year Ended December 31, 2010
Date:2/1/2011

cted procedural volumes; new product approvals, launches and sales; regulatory compliance; our market position; cash flow; write-down of goodwill and other asset impairments; our capacity to fund acquisitions and other investments and to successfully complete acquisitions and integrate them into our business; our ability to successfully separate our Neurovascular business; our ability to reduce our debt obligations; and our restructuring activities.
If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.
These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.
As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions and the market acceptance of those products; clinical trial results; demographic trends; intellectual property; litigation; financial market conditions; the effect of our goodwill impairment charges and our restructuring initiatives; closing of announced acquisitions and integration of acquired companies; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - 
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System
2. Boston Scientific Responds to DOJ Civil Lawsuit
3. Boston Scientific Announces First Use of Blazer® Open-Irrigated Catheter in U.S.
4. Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent
5. Boston Scientific Completes Enrollment in EVOLVE Clinical Trial to Evaluate SYNERGY™ Drug-Eluting Coronary Stent
6. Boston Scientific Announces Agreement With Fukuda Denshi for Distribution of Cardiac Rhythm Management Products in Japan
7. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2010 Financial Results
8. Boston Scientific to Acquire Atritech
9. Boston Scientific Completes Enrollment in Clinical Trial Evaluating Next-Generation Nitinol Stent to Treat Iliac Artery Disease
10. Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article
11. Boston Scientific Completes Acquisition of Sadra Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 /PRNewswire/ - Anything Technologies Media, Inc. (OTC:EXMT) has ... Garden Solutions (FIGS), www.frontiergarden.com has been ... Project Manager for a My Compassion originated medical ... located in Alaska.  The project will be funded ... Teaming Partners. The first phase of the project, ...
(Date:7/30/2015)... 30, 2015  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... and webcast at 5:00 p.m. Eastern Time (2:00 p.m. ... second quarter 2015 financial results and provide a corporate ... NASDAQ Global Select Market closes that day. ... for domestic callers and 914.495.8552 for international callers. Please ...
(Date:7/30/2015)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), ... and commercialization of prescription ophthalmic pharmaceuticals, today announced that ... financial results after the market close on Monday, August ... the same day at 4:30 p.m. ET. ... Officer, and Rick Eiswirth , Chief Operating Officer ...
Breaking Medicine Technology:Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 2Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2
... Nov. 11 Pharma market research thought leaders are discovering ... opportunities in the pharmaceutical industry. The last twelve months ... Pharmaceutical market research is no exception. But those ... information today will certainly rise to be the new leaders ...
... VVUS ) today announced that Timothy Morris, chief financial officer, ... Markets 6th Annual Healthcare Conference. , The VIVUS presentation will take ... November 18, 2009 at 1:45 p.m. ET. A live webcast ... http://ir.vivus.com . , About VIVUS ...
Cached Medicine Technology:Executives Reveal Secrets to Capitalize on New Developments in Pharmaceutical Marketing Research 2VIVUS to Present at Lazard Capital Markets Healthcare Conference 2
(Date:7/30/2015)... WASHINGTON (PRWEB) , ... July 30, 2015 , ... ... the scientific program at ATA’s 21st Annual Meeting and Tradeshow focused exclusively on ... more than 300 cutting-edge health care technology vendors, will take place May 14-17, ...
(Date:7/30/2015)... County, CA (PRWEB) , ... July 30, 2015 , ... ... County, Los Angeles, Riverside, and San Bernardino, recently announced that the Centers for Medicare ... new rating system of home health care providers. 24/7 Care At Home’s agency is ...
(Date:7/30/2015)... ... ... Ross A. Clevens, MD, FACS has been reappointed by the University ... This is Dr. Clevens’ second appointment by the prestigious school. Over the past ... and a valuable mentoring program for medical students. , The University ...
(Date:7/30/2015)... Los Angeles, California (PRWEB) , ... July 30, 2015 , ... ... of the success of the 2015 Special Olympics World Games, the largest sports and ... Angeles since the 1984 Olympic Games. , The World Games, held July 25 through ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Ocean Hills ... available, including the very rare “no recommendations.” No recommendations means CARF found no areas ... is a notation that less than 3% of all facilities receive. In addition, Ocean ...
Breaking Medicine News(10 mins):Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2
... City of Hope leads study showing efficacy of ... ... National,Marrow Donor Program (NMDP) has selected an abstract written by Dr.,Auayporn Nademanee, ... City of Hope, and Dr. Robert Chow,Founder and Global Medical Director for ...
... World Diabetes Day, November 14,is observed every year ... by others with an interest in diabetes. This year,s ... excellent opportunity,to focus on the significant increase in type ... Funded by the National Institutes of Health (NIH), researchers ...
... Percent of People with ... (Spinal Arthritis), ABBOTT PARK, Ill., Nov. 8 A ... decrease in the rate of uveitis flares by approximately half ... of the spine, and may also be associated with other ...
... Corporation,(Nasdaq: RGEN ) today reported results for the ... Total revenue for the quarter was,$5,352,000 compared to $2,865,000 ... 30, 2006, an increase of $2,487,000 or 87%. Total,revenue ... revenue.,Gross profit on product revenue for the second quarter ...
... IDMI ) today announced its financial results for ... information presented,represents the consolidated results of IDM Pharma and ... $33.2 million as of September 30,2007 compared to $37.3 ... 31, 2006. The Company,s net cash outflow from operations ...
... health diagnosis at the point-of-care and begin triage faster and easier ... ... UNION CITY, Calif., Nov. 8 Abaxis, Inc.,(Nasdaq: ABAX ), ... the U.S. Food and Drug,Administration (FDA) has granted waived status under ...
Cached Medicine News:Health News:Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program 2Health News:Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program 3Health News:Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program 4Health News:World Diabetes Day Spotlights Type 1 Diabetes Increase and World Class Response 2Health News:World Diabetes Day Spotlights Type 1 Diabetes Increase and World Class Response 3Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 2Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 3Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 4Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 5Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 6Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 2Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 3Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 4Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 5Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 6Health News:Repligen Reports Second Quarter Fiscal Year 2008 Financial Results 7Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 2Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 3Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 4Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 5Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 6Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 7Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 8Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 9Health News:IDM Pharma Reports Third Quarter 2007 Financial Results 10Health News:Abaxis Announces First Ever CLIA-Waived Comprehensive Metabolic Panel 2Health News:Abaxis Announces First Ever CLIA-Waived Comprehensive Metabolic Panel 3Health News:Abaxis Announces First Ever CLIA-Waived Comprehensive Metabolic Panel 4
... new Oculus Easygraph is a corneal ... tools you need for refractive surgery, ... therapy contact lens fitting in a ... 4" package. All you need to ...
The only ergonomic work station of its kind with an optional built-in keratograph and flat-screen. The Concepta is a modern workstation for the examination and refraction of patients....
The natural look of 3 in 1 technology in virtually any prescription....
Dot matrix pattern for light eyed patients....
Medicine Products: